CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Multiple analysts have issued price targets for $CRSP recently. We have seen 15 analysts offer price targets for $CRSP in the last 6 months, with a median target of ...

Recent discussions on X about CRISPR Therapeutics (CRSP) have been buzzing with excitement following the company's stock hitting a 52-week high of $62.32 and news of a significant insider purchase by ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on Friday. CRSP has been the subject of a number of other reports. Citigroup ...

What Is CRSP? The Center for Research in Security Prices has been around for more than 60 years, and its wonky name is explained by the fact that it was a project originally undertaken by academics at ...